



## **Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases**

-- Safety and pharmacokinetic results support continued Phase 2 development of ASN100 --

-- Preclinical data also to be presented for ASN100 and pipeline programs --

**WALTHAM, Mass. and VIENNA, Austria – April 20, 2017** – Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the company will be reporting data in five poster presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria, April 22 – 25, 2017. The data will highlight the Phase 1 safety and pharmacokinetics of ASN100, the company's lead clinical candidate currently being evaluated in a Phase 2 trial for the prevention of *Staphylococcus aureus* pneumonia in high-risk, mechanically ventilated patients as well as new research findings for ASN100 and two pre-clinical mAb programs, ASN200 and ASN300, which target infections caused by multi-drug resistant strains of the Gram-negative pathogens *Escherichia coli* and *Klebsiella pneumoniae*.

"We are pleased to share the first clinical data for ASN100 at the 27<sup>th</sup> ECCMID, an integral step in expanding our understanding of the safety and potential efficacy of ASN100 to address serious *S. aureus* infections through a novel, non-antibiotic approach," said Chris Stevens, M.D., Chief Medical Officer, Arsanis.

"In addition to ASN100, Arsanis continues to advance a pre-clinical pipeline of targeted, precision monoclonal antibody therapies that address important bacterial and viral pathogens," said Eszter Nagy, M.D., Ph.D., co-founder and Chief Scientific Officer, Arsanis. "We look forward to sharing new research findings within our *S. aureus* and Gram-negative pipeline programs that address the unique underlying biology and virulence mechanisms of each targeted pathogen."

Arsanis has also been invited to present a company pipeline overview at the ECCMID Pipeline Corner on April 23, 12:30 – 1:20 p.m. CEST, in Foyer E (between Halls D and E).

The following abstracts will be presented at ECCMID as an exchange of scientific and clinical information (all times CEST):

### ASN100-related Abstracts

Poster Presentation P0469; Saturday, April 22, 3:30 – 4:30 p.m.

Efficacy of ASN100, a combination of two human monoclonal antibodies neutralizing six *Staphylococcus aureus* cytotoxins, in a CA-MRSA rabbit necrotizing pneumonia model

Authors: L. Stulik (Vienna, Austria), D. Labrousse, D. Croisier, G. Nagy, E. Nagy

Poster Presentation P0470; Saturday, April 22, 3:30 – 4:30 p.m.

Synergistic inhibition of the concerted action of six *Staphylococcus aureus* cytotoxins with ASN100, a combination of two human monoclonal antibodies

Authors: H. Rouha (Vienna, Austria), B. Maierhofer, K. Gross, A. Badarau, I. Dolezilkova, S. Weber, L. Stulik, E. Nagy

Poster Presentation P0471; Saturday, April 22, 3:30 – 4:30 p.m.

Safety and pharmacokinetics of ASN100, a monoclonal antibody combination for the prevention and treatment of *Staphylococcus aureus* infections, from a single ascending dose Phase 1 clinical study in healthy adult volunteers  
Authors: Z. Magyarics (Vienna, Austria), F. Leslie, S. Luperchio, J. Bartko, C. Schörghofer, M. Schwameis, U. Derhaschnig, H. Lagler, L. Stiebellehner, B. Jilma, E. Nagy, C. Stevens

#### ASN200-related Abstract

Poster Presentation P0466; Saturday, April 22, 3:30 – 4:30 p.m.

Monoclonal antibody specific to the *Escherichia coli* ST131-O25b clonal lineage shows bactericidal and anti-inflammatory activity against a clinical isolate carrying plasmid-encoded colistin resistance

Authors: L. Guachalla (Vienna, Austria), K. Hartl, A. Ghazawi, T. Pal, A. Sonnevend, G. Nagy, V. Szijarto

#### ASN300-related Abstract

Poster Presentation P0465; Saturday, April 22, 3:30 – 4:30 p.m.

LPS neutralization is the main mode of action of an O-antigen-specific monoclonal antibody protective against *Klebsiella pneumoniae* ST258

Authors: G. Nagy (Vienna, Austria), V. Szijarto, L. Guachalla, K. Hartl, C. Varga, E. Nagy

#### **About ASN100**

ASN100 is a combination of two fully human monoclonal antibodies that collectively neutralize six important *Staphylococcus aureus* cytotoxins associated with pneumonia pathogenesis. ASN-1 neutralizes alpha-hemolysin (Hla), a key *S. aureus* toxin responsible for lung epithelial cell damage, in addition to four *S. aureus* leukocidins responsible for lysis of human phagocytic (immune) cells: Pantone-Valentine leukocidin (PVL), leukocidin ED, and gamma-hemolysins AB and CB. ASN-2 inactivates another *S. aureus* leukocidin, LukGH, a particularly potent human cytotoxin also responsible for lysis of human phagocytes. ASN100 is being evaluated in a Phase 2 clinical study for the prevention of *S. aureus* pneumonia in high-risk, mechanically ventilated patients, and has received Fast Track designation from the U.S. FDA.

#### **About Arsanis, Inc.**

Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company's current programs address pathogenic processes selectively, rather than aiming to broadly eliminate pathogens, potentially allowing Arsanis to address critical infections without contributing to the problem of antimicrobial resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is being evaluated in a Phase 2 clinical study for the prevention of *Staphylococcus aureus* pneumonia in high-risk patients.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

For more information, please visit the Arsanis website at [www.arsanis.com](http://www.arsanis.com).

###

#### **Media Contact:**

Ten Bridge Communications

Krystle Gibbs

krystle@tenbridgecommunications.com, 508-479-6358

#### **Investor Contact:**

Michael Gray

Chief Financial and Chief Business Officer

mike.gray@arsanis.com, 781-819-5201